Beigelman Leonid 4
4 · Aligos Therapeutics, Inc. · Filed Feb 8, 2022
Insider Transaction Report
Form 4
Beigelman Leonid
DirectorPresident
Transactions
- Award
Stock Option (Right to Buy)
2022-02-04+56,700→ 56,700 totalExercise: $3.06Exp: 2032-02-04→ Common Stock (56,700 underlying) - Award
Stock Option (Right to Buy)
2022-02-04+226,800→ 226,800 totalExercise: $3.06Exp: 2032-02-04→ Common Stock (226,800 underlying)
Footnotes (2)
- [F1]1/48th of the total number of shares vest in forty-eight (48) successive and equal monthly installments measured from February 4, 2022 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
- [F2]100% of the shares subject to the Option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through such vesting date.